DUBLIN--(BUSINESS WIRE)--The "Global Myeloproliferative Disorders Drugs Market (2018-2023): Size, Share & Trends Analysis" report has been added to ResearchAndMarkets.com's offering.
There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group. The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to presence of a large target population.
Further key findings from the report suggest:
- The U.S. accounted for more than 45% of the market in 2017. Spiraling adoption of novel therapeutics and multiple product launches during the forecast period are anticipated to support the prominence of the market in global arena over the coming years.
- Strong unmet needs are likely to shape the future of the market and encourage development of breakthrough first-in-class therapies. Opportunities remain in the Ph- MPNs setting where there exists an unmet need for a safer drug than Jakafi with higher cure rates and lesser allergic effects.
-
Primary go-to strategies of prominent players include collaborations
for development and regional expansion in emerging markets.
- Novartis
- Bristol-Myers Squibb
- Pfizer
- Takeda
- Inctye
- Teva
Key Topics Covered
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
Chapter 4 Global Myeloproliferative Disorders Drugs Market Overview
Chapter 5 Myeloproliferative Disorders Market: Pipeline Intelligence
Chapter 6 Company Profiles
Chapter 7 Market Outlook
For more information about this report visit https://www.researchandmarkets.com/research/79w49p/global?w=4
